Data from Japan suggest that pathogenic variants are associated with increased risk for a broad group of malignancies.
Germline mutations in BRCA1 and BRCA2 are known to increase the risk for several cancers, including breast, ovarian, pancreatic, and prostate. Reports have suggested that risk for biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancer may also be increased in those harboring pathogenetic variants of BRCA1 and BRCA2, and data suggest that elevation of risk for specific cancers may vary across populations in different regions of the world. Investigators undertook a large-scale, registry-based study to analyze DNA and clinical information from individuals across Japan from 2003 through 2018. More than 65,000 patients (median age, 64 years; 42% female) and about 38,000 controls (median age, 62 years; 47% female) were i…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)